75 related articles for article (PubMed ID: 21316958)
1. Maintaining potent HTLV-I protease inhibition without the P3-cap moiety in small tetrapeptidic inhibitors.
Nguyen JT; Kato K; Kumada HO; Hidaka K; Kimura T; Kiso Y
Bioorg Med Chem Lett; 2011 Mar; 21(6):1832-7. PubMed ID: 21316958
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles.
Nguyen JT; Kato K; Hidaka K; Kumada HO; Kimura T; Kiso Y
Bioorg Med Chem Lett; 2011 Apr; 21(8):2425-9. PubMed ID: 21392990
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties.
Zhang M; Nguyen JT; Kumada HO; Kimura T; Cheng M; Hayashi Y; Kiso Y
Bioorg Med Chem; 2008 May; 16(10):5795-802. PubMed ID: 18400502
[TBL] [Abstract][Full Text] [Related]
4. Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors.
Nguyen JT; Zhang M; Kumada HO; Itami A; Nishiyama K; Kimura T; Cheng M; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2008 Jan; 18(1):366-70. PubMed ID: 18006315
[TBL] [Abstract][Full Text] [Related]
5. Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme.
Zhang M; Nguyen JT; Kumada HO; Kimura T; Cheng M; Hayashi Y; Kiso Y
Bioorg Med Chem; 2008 Jul; 16(14):6880-90. PubMed ID: 18558491
[TBL] [Abstract][Full Text] [Related]
6. Chipping at large, potent human T-cell leukemia virus type 1 protease inhibitors to uncover smaller, equipotent inhibitors.
Kimura T; Nguyen JT; Maegawa H; Nishiyama K; Arii Y; Matsui Y; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2007 Jun; 17(12):3276-80. PubMed ID: 17448657
[TBL] [Abstract][Full Text] [Related]
7. Substrates and inhibitors of human T-cell leukemia virus type I protease.
Ding YS; Rich DH; Ikeda RA
Biochemistry; 1998 Dec; 37(50):17514-8. PubMed ID: 9860866
[TBL] [Abstract][Full Text] [Related]
8. Development of [Ile⁴⁰]HTLV-I protease inhibition assay using novel fluorogenic and chromogenic substrate.
Kumada HO; Nguyen JT; Kakizawa T; Hidaka K; Kimura T; Hayashi Y; Kiso Y
J Pept Sci; 2011 Aug; 17(8):569-75. PubMed ID: 21574213
[TBL] [Abstract][Full Text] [Related]
9. Substrates and inhibitors of human T-cell leukemia virus type 1 (HTLV-1) proteinase.
Hrusková-Heidingsfeldová O; Bláha I; Urban J; Strop P; Pichová I
Leukemia; 1997 Apr; 11 Suppl 3():45-6. PubMed ID: 9209292
[TBL] [Abstract][Full Text] [Related]
10. Privileged Structures Meet Human T-Cell Leukemia Virus-1 (HTLV-1): C2-Symmetric 3,4-Disubstituted Pyrrolidines as Nonpeptidic HTLV-1 Protease Inhibitors.
Kuhnert M; Blum A; Steuber H; Diederich WE
J Med Chem; 2015 Jun; 58(11):4845-50. PubMed ID: 26000468
[TBL] [Abstract][Full Text] [Related]
11. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
[TBL] [Abstract][Full Text] [Related]
12. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of inhibitor complexes of human T-cell leukemia virus (HTLV-1) protease.
Satoh T; Li M; Nguyen JT; Kiso Y; Gustchina A; Wlodawer A
J Mol Biol; 2010 Aug; 401(4):626-41. PubMed ID: 20600105
[TBL] [Abstract][Full Text] [Related]
14. The protease of human T-cell leukemia virus type-1 is a potential therapeutic target.
Tözsér J; Weber IT
Curr Pharm Des; 2007; 13(12):1285-94. PubMed ID: 17504236
[TBL] [Abstract][Full Text] [Related]
15. Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease.
Kádas J; Weber IT; Bagossi P; Miklóssy G; Boross P; Oroszlan S; Tözsér J
J Biol Chem; 2004 Jun; 279(26):27148-57. PubMed ID: 15102858
[TBL] [Abstract][Full Text] [Related]
16. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
[TBL] [Abstract][Full Text] [Related]
17. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Njoroge FG; Chen KX; Shih NY; Piwinski JJ
Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of activity of the protease from bovine leukemia virus.
Ménard A; Leonard R; Llido S; Geoffre S; Picard P; Berteau F; Precigoux G; Hospital M; Guillemain B
FEBS Lett; 1994 Jun; 346(2-3):268-72. PubMed ID: 8013645
[TBL] [Abstract][Full Text] [Related]
19. The human T-cell leukemia virus type 1 (HTLV-1): new insights into the clinical aspects and molecular pathogenesis of adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM).
Shuh M; Beilke M
Microsc Res Tech; 2005 Nov; 68(3-4):176-96. PubMed ID: 16276549
[TBL] [Abstract][Full Text] [Related]
20. Effect of prime-site sequence of retro-inverso-modified HTLV-1 protease inhibitor.
Awahara C; Tatsumi T; Furuta S; Shinjoh G; Konno H; Nosaka K; Kobayashi K; Hattori Y; Akaji K
Bioorg Med Chem; 2014 Apr; 22(8):2482-8. PubMed ID: 24680060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]